RESUMO
INTRODUCTION: Sorafenib improves progression-free survival in advanced clear-cell renal-cell carcinoma patients progressing to first-line therapy, as has been shown in the placebo-controlled international TARGET trial. The aim of this study is to report the results of the patients included in the Spanish centres in this trial. PATIENTS AND METHODS: The records of the patients in the database of the TARGET trial have been reviewed. Data about progression-free survival, overall survival and toxicity have been collected in order to do this subpopulation analysis. RESULTS: A total of 15 patients have been included (sorafenib arm 7, placebo arm 8). A trend to an improved progression-free survival in the sorafenib arm has been observed period Toxicity in the sorafenib arm has been manageable. CONCLUSION: The analysis of these 15 patients has shown efficacy and toxicity results that follow the trend observed for the overall international population.
Assuntos
Antineoplásicos/uso terapêutico , Benzenossulfonatos/uso terapêutico , Carcinoma de Células Renais/tratamento farmacológico , Neoplasias Renais/tratamento farmacológico , Piridinas/uso terapêutico , Idoso , Antineoplásicos/efeitos adversos , Benzenossulfonatos/efeitos adversos , Intervalo Livre de Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Niacinamida/análogos & derivados , Compostos de Fenilureia , Piridinas/efeitos adversos , Sorafenibe , Espanha , Resultado do TratamentoRESUMO
The combination of ifosfamide and irinotecan was tested in a dose-finding study. The preliminary results of the combination in this phase I study did not show any major toxicity that could help to define the dose-limiting toxicity. The escalation continues even after nine levels; the study is therefore ongoing. The main toxicity is gastrointestinal, with mild nausea, vomiting, and diarrhea. There was some other irrelevant toxicity, which was easily manageable with the usual supportive therapy. When responses were evaluated, stable disease was found in some cases, suggesting some activity for the combination.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Ifosfamida/administração & dosagem , Neoplasias/tratamento farmacológico , Terapia de Salvação , Adulto , Idoso , Camptotecina/administração & dosagem , Camptotecina/análogos & derivados , Feminino , Humanos , Irinotecano , Masculino , Pessoa de Meia-IdadeRESUMO
We present a solar recharging system for nickel-cadmium cells of interest in areas where batteries for hearing aids are difficult to obtain. The charger has sun cells at the top. Luminous energy is converted into electrical energy, during the day and also at night if there is moonlight. The cost of the charger and hearing aid is very low at 35 US$. The use of solar recharging for hearing aids would be useful in alleviating the problems of deafness in parts of developing countries where there is no electricity.
Assuntos
Auxiliares de Audição , Energia Solar , Países em Desenvolvimento , Eletricidade , Fatores de TempoRESUMO
This paper deals with the auditory brainstem responses and its clinical application to the assessment of hearing losses, degree of severity and topographic diagnosis, in children.
Assuntos
Potenciais Evocados Auditivos do Tronco Encefálico , Perda Auditiva Neurossensorial/diagnóstico , Testes de Impedância Acústica , Pré-Escolar , Cóclea/fisiopatologia , Perda Auditiva Neurossensorial/fisiopatologia , Humanos , Lactente , Recém-NascidoRESUMO
Surgery practice, as day cases, is as old as surgery itself, but actually because of the assembly of present-day circumstances, specially the shortage of ward beds, make necessary to gain advantage of resources available. The new requests for medical attendance as well the technological novelties have influenced at Hospital de Cruces to establish the Outpatients Surgical Unit. A good organisation allows the Adeno-tonsillectomy surgery with little risk in these Unities. We describe our experience, the advantages and the complications of this behavior.